BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharma (PCRX) Tops Q3 EPS by 4c
October 30, 2014 6:30 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.14, $0.04 better than the analyst estimate of $0.10. Revenue for the quarter came in at $52 million versus the consensus estimate of $52.2 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More